A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-Acting Injectable Risperidone in Patients With Schizophrenia.
This study has been completed.
Study NCT00034775
Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: May 2, 2002
Last Updated: March 14, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
